{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:06:10Z","timestamp":1777421170950,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Heart failure is a major public health concern with a rising prevalence and significant financial detriment. Although sacubitril\/valsartan was shown to reduce the risk of death and hospitalization from heart failure in a contemporary cohort, it continues to remain substantially underutilized. A recent article in the Annals highlights the evidence behind inpatient initiation of sacubitril\/valsartan. We provide further considerations and summarize the evidence for inpatient initiation of other guideline directed medical therapies. Overall, there is a need to improve methods to identify ideal populations and increase utilization in those who may benefit from sacubitril\/valsartan. Further research is also needed to identify the risks versus benefits among underrepresented populations (i.e., advanced heart failure, heart failure with preserved ejection fraction, in conjunction with other contemporary evidence-based therapies that can lower blood pressure, etc.).<\/jats:p>","DOI":"10.1177\/1060028020964923","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T06:18:14Z","timestamp":1603865894000},"page":"805-813","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril\/Valsartan"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-7300","authenticated-orcid":false,"given":"Michael","family":"Gillette","sequence":"first","affiliation":[{"name":"Michael DeBakey VA Medical Center & Baylor College of Medicine, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Michael DeBakey VA Medical Center & Baylor College of Medicine, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"bibr1-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020947446"},{"key":"bibr2-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928"},{"key":"bibr3-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"bibr4-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000"},{"key":"bibr5-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"bibr6-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr7-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.008"},{"key":"bibr8-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.03.048"},{"key":"bibr9-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.040"},{"key":"bibr10-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004675"},{"key":"bibr11-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.05.008"},{"key":"bibr12-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.12.002"},{"key":"bibr13-1060028020964923","first-page":"A19094","volume":"132","author":"Siddiqui M","year":"2015","journal-title":"Circulation"},{"key":"bibr14-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.08.036"},{"key":"bibr15-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.11.006"},{"key":"bibr16-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.14795"},{"key":"bibr17-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041137"},{"key":"bibr18-1060028020964923","doi-asserted-by":"publisher","DOI":"10.10\/j.amjcard.2011.02.322"},{"key":"bibr19-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"bibr20-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.08.711"},{"key":"bibr21-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2006.11.015"},{"key":"bibr22-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2198"},{"key":"bibr23-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.838"},{"key":"bibr24-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.112.972240"},{"key":"bibr25-1060028020964923","author":"Maddox T","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"bibr26-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"bibr27-1060028020964923","unstructured":"Novartis Pharmaceuticals. Changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with Acute Decompensated Heart Failure (ADHF) who have been Stabilized during Hospitalization and Initiated In-Hospital or Within 30 Days Post-Discharge (PARAGLIDE-HF). Updated May 15, 2020. Accessed September 16, 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03988634"},{"key":"bibr28-1060028020964923","unstructured":"Zhenhua Zen. Hypertension in patients hospitalized with COVID-19 (HT-COVID19). Updated April 29, 2020. Accessed September 28, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318301"},{"key":"bibr29-1060028020964923","unstructured":"Neuromed IRCCS. ACE inhibitors, angiotensin II type-1 receptor blockers and severity of COVID-19. (CODIV-ACE). Updated September 16, 2020. Accessed September 28, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318418"},{"key":"bibr30-1060028020964923","unstructured":"University of Minnesota. Losartan for patients with COVID-19 requiring hospitalization. Updated July 21, 2020. Accessed September 28, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009"},{"key":"bibr31-1060028020964923","unstructured":"University of Minnesota. Losartan for patients with COVID-19 not requiring hospitalization. Updated June 16, 2020. Accessed September 28, 2020."},{"key":"bibr32-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317393"},{"key":"bibr33-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.05.002"},{"key":"bibr34-1060028020964923","unstructured":"National University of Ireland, Galway, Ireland. Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION). Updated June 30, 2020. Accessed September 28, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330300"},{"key":"bibr35-1060028020964923","unstructured":"Assistance Publique\u2014H\u00f4pitaux de Paris. ACE inhibitors or ARBs discontinuation in context of SARS-COV-2 pandemic (ACORES-2). Updated June 4, 2020. Accessed September 28, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04329195"},{"key":"bibr36-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923"},{"key":"bibr37-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760"},{"key":"bibr38-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.040"},{"key":"bibr39-1060028020964923","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020964923","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020964923","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020964923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:56Z","timestamp":1777374956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020964923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1060028020964923"],"URL":"https:\/\/doi.org\/10.1177\/1060028020964923","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]}}}